Syphilis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

March 16, 2012 - PRLog -- GlobalData estimates that the global syphilis therapeutics market’s value at $11.9m in 2011, after increasing at a Compound Annual Growth Rate (CAGR) of 6.0% during 2006–2011. The market is expected to record a CAGR of 3.9% from 2011–2019, to $16.2m by 2019.

At present, the syphilis therapeutic market is dominated by generics. The main drug which is used for the treatment of syphilis is penicillin G benzathine. The individuals who are allergic to penicillin are given alternative treatment with antibiotics such as doxycycline, erythromycin, tetracycline and azithromycin. The available drugs have high safety and efficacy profiles and they are able to meet the current market need of the patients with early syphilis.

GlobalData’s analysis found that slow growth recorded in the syphilis therapeutic market during 2006-
2011, was primarily attributed to the availability of generics in the market, which causes volume sales rather than value sales. Moreover, during the forecast period as well the market is expected to show slow growth due to the unavailability of any molecule in the syphilis therapeutics pipeline.

GlobalData’s analysis indicates that syphilis therapeutics market has low unmet need. However, unmet need exists in terms of late diagnosis of the disease. This lack of early diagnosis may lead to further disease progression to the late stages of the disease. Syphilis is easily cured during the early stages, but during the late stages much damage is caused to the various organs and the damage is irreversible. Although the available therapies prevent the further progression of the disease during the late stages it is not able to cure the damage which is already done. So, unmet need exists in the need for a drug which could treat patients of late stage syphilis more effectively.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....


GlobalData’s analysis indicates that the current competition in the syphilis therapeutics market is weak due to the low number of options available for the treatment of syphilis. Currently the marketed drug for syphilis which is most often used is penicillin G benzathine. But individuals who are allergic to penicillin are given an alternative therapy of antibiotics as the antibiotics which are used for the treatment of syphilis are doxycycline, tetracycline, erythromycin and azithromycin.

GlobalData, the industry analysis specialist, has released its new report, “Syphilis Therapeutics – Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global syphilis therapeutics market. The report identifies the key trends shaping and driving the global syphilis therapeutics market. The report also provides insights on the prevalent competitive landscape and emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global syphilis therapeutics market sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Syph...


Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.